Kelun, Merck's lung cancer combo improves survival in late-stage China trial

Sichuan Kelun-Biotech said its experimental therapy combined with Merck's Keytruda improved survival in patients with advanced lung cancer, meeting the primary endpoint of a late-stage study. The result is a positive clinical milestone for the program and supports the drug candidate's development prospects. The news is company-specific and could be supportive for sentiment, but it is not yet an approval or commercial launch.

Analysis

Sichuan Kelun-Biotech said its experimental therapy combined with Merck's Keytruda improved survival in patients with advanced lung cancer, meeting the primary endpoint of a late-stage study. The result is a positive clinical milestone for the program and supports the drug candidate's development prospects. The news is company-specific and could be supportive for sentiment, but it is not yet an approval or commercial launch.